Table 3. Adverse Events^a.

Adverse event	Patients, No. (%)
	Bimagrumab group	Placebo group
Death	0	0
Serious adverse events	3 (8)	3 (8)
Any adverse event	31 (84)	31 (82)
Adverse event leading to study discontinuation	5 (14)	0
Most frequent adverse eventsb
Diarrhea	15 (41)	4 (11)
Muscle spasms	15 (41)	1 (3)
Upper respiratory tract infection	6 (16)	5 (13)
Lipase level increased	4 (11)	2 (5)
Headache	0	5 (13)
Hypertension	3 (8)	1 (3)
Nausea	4 (11)	0
Rash	2 (5)	2 (5)

^a Adverse events were any untoward medical occurrence in a patient who provided written informed consent for participation in the study until the end of study visit.

^b Incidence greater than 5%.